Cognito Therapeutics, Inc.

Thanks Medical Design & Outsourcing for speaking with our CEO Christian Howell and Chief Strategy Officer Pritesh Shah, PharmD. We share how Cognito is staying mission-focused and advancing new therapies for Alzheimer's disease. “What doesn’t change is real clarity to the problem you’re solving,” he said. “Oftentimes we lose sight of that. We get caught up in the design reviews and the engineering and the studies, but [you need] to clearly articulate and validate the problem that you are addressing and why it has been unmet, and then how you are going about and solving that problem in a novel or unique way. … I don’t think until you’ve had a family member or until you’ve been a caregiver, that you understand what [Alzheimer’s] takes from people and how brutal the disease is.” At Cognito, we remain committed to delivering innovative, non-invasive solutions for patients and their families. 🧠 Read more about our journey and vision here: https://lnkd.in/dbn7mxC5 #Neurotech #MedTech #Alzheimers #Innovation #Leadership

Our CMO Ralph Kern spoke with NeurologyLive at the recent #ADPD25 conference. 🧠🧠 Our noninvasive Spectris device, utilizing 40 Hz gamma frequency stimulation, has demonstrated promising results in slowing Alzheimer's disease progression. Phase 2 data revealed significant preservation of white matter structures, particularly the corpus callosum, and a reduction in brain atrophy rates. These findings suggest potential neuroprotective effects and underscore the importance of targeting white matter integrity in #Alzheimer's treatment. As we advance our pivotal HOPE trial, we're optimistic about the role of gamma sensory stimulation in enhancing brain resilience and function. For a detailed overview, watch Dr. Ralph Kern's interview on NeurologyLive: https://lnkd.in/eBAPWAy9 #AlzheimersResearch #NeuroInnovation #GammaStimulation #CognitoTherapeutics #SpectrisDevice #NeurologyLive

PART 2 ⬇️ 🌟 We're thrilled to bring together some of the brightest minds in clinical research at the Precision in Clinical Trials Summit (PCT) Boston, happening April 28–29, 2025 at the Revere Hotel Boston Common! 🏙️ This summit is set to be a hub for innovation, collaboration, and impactful discussions that will shape the future of clinical trials. Whether you're a seasoned leader or a rising star in the space, this is your chance to connect, learn, and grow. 💡 🔗Email info@Precision-globe.com to register! #PCTSummit #ClinicalTrials #Biopharma #LifeSciences #ConferenceSeason

At #ADPD2025, held April 1-5 in Vienna, Austria, Cognito Therapeutics, Inc. presented a pair of posters highlighting its gamma sensory stimulation device in patients with #Alzheimers disease. In these data, findings showed that sensory stimulation delivered by Spectris effectively evoked 40 Hz steady-state oscillation, and led to preserved corpus callosum area structure when compared with matched participants from the Alzheimer’s Disease Neuroimaging Initiative. https://hubs.li/Q03f-61d0

🧠 New data from #ADPD25 highlights the potential of Cognito’s gamma sensory stimulation to preserve brain structure in Alzheimer’s disease. In a new interview with NeurologyLive, our Chief Medical Officer Dr. Ralph Kern, shared insights from two Cognito posters presented at the AD/PD International Conference. Thanks Marco Meglio for speaking with us. 🔬 The findings? Patients using our #Spectris™ device showed preserved structure in the corpus callosum—a critical white matter bridge between the brain's hemispheres—compared to matched controls from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). ✅ Spectris evoked consistent 40 Hz gamma oscillations, which were correlated with white matter volume, cortical thickness, and brain resilience markers—suggesting a novel, non-invasive way to slow structural degeneration in Alzheimer’s. 🧩 “We’re using physics to treat brain chemistry and biology, leveraging sensory stimulation to drive brain-wide changes. The support we’ve received from the Alzheimer’s community reflects growing excitement around this innovative approach, and we’re eager to see how it translates into clinical outcomes. Our technology is designed to restore disrupted brain rhythms and promote resilience in a disease that’s desperately in need of new approaches.” - Ralph Kern With Phase 3 enrollment for our HOPE study nearly complete, we’re energized by the growing clinical and scientific support for a physics-driven, drug-free approach to treating Alzheimer’s. Learn more about HOPE: https://lnkd.in/eyvfmbWK 🔗 Full interview with Dr. Kern via NeurologyLive: https://lnkd.in/e-TTXNe4 #ADPD2025 #Alzheimers #Neurotech #Spectris #Neurology #BrainHealth #WhiteMatter

What role does Gamma Stimulation therapy have in the treatment of #AD? How does a physics-based approach differ from what’s on market? Stay tuned for NeurologyLive's conversation with our CMO Ralph Kern, MD, who discussed the company’s device, #Spectris and its effect on corpus callosum. Thanks Marco Meglio for speaking with us!

Thanks FirstWord HealthTech for covering our recent news at #ADPD25. 🧠🧠 CEO Christian Howell told FirstWord that Spectris is a device designed for at-home use, stating that it works by delivering carefully timed light and sound stimulation that reactivates specific neuroelectrical rhythms associated with brain health. Each device is calibrated to match the unique tolerance and response levels of the individual using it. "In a healthy brain, these rhythms support key biological processes that maintain neural structure and function," Howell said. "However, in #Alzheimer’s disease, this activity is disrupted — limiting the brain’s ability to sustain normal functions." Read the article: https://lnkd.in/eWgYtbqn

Thanks MassDevice for covering our recent news at #ADPD25. Cognito Therapeutics today announced new data from its OVERTURE feasibility trial evaluating its Spectris neuromodulation system. The company designed its non-invasive Spectris device to deliver proprietary gamma frequency light and sound stimulation. This evokes EEG-confirmed gamma frequency brain oscillations to treat central nervous system (CNS) diseases. Read the article by Sean Whooley: https://lnkd.in/e5h2xjQP

We’re excited to announce new data from our OVERTURE feasibility trial at the AD/PD™ 2025 International Conference on Alzheimer’s and Parkinson’s Diseases. The results showed that #Spectris™, our non-invasive investigational neuromodulation device, maintains corpus callosum structure and evokes gamma oscillation responses that correlate with baseline brain structure in patients with mild-to-moderate Alzheimer’s disease. “These new findings provide strong, complementary evidence that Spectris not only engages an important neurophysiological target, but also maintains structural integrity in the Alzheimer’s brain,” said Christian Howell, Chief Executive Officer, Cognito Therapeutics. “With no observed amyloid-related imaging abnormalities (ARIA) convenient at-home use, and mounting clinical and mechanistic evidence, we believe Spectris is poised to become a transformative therapy for Alzheimer’s disease.” Read the release: https://lnkd.in/en2Z3iqD

🧠 Excited to announce that Cognito Therapeutics will be presenting new data at #ADPD25 in Vienna this week! Our team will be on-site and looking forward to meeting you this week. Our latest findings from the OVERTURE study show that Spectris™, our investigational disease-modifying therapy, may preserve brain structure and slow neurodegeneration in patients with #Alzheimer’s disease. 🔬 New MRI imaging analyses revealed that Spectris™ treatment correlates with preserved integrity in key brain regions like the corpus callosum, a critical structure for cognitive function. 🗓️ Join us for our two presentations on April 2: 📍 Sensory Evoked Gamma Oscillation Correlates with Brain Morphology in Alzheimer’s Disease Presenter: Mihaly Hajos, PhD | 8:00 – 10:00 AM CET 📍 Spectris™ Treatment Preserves Corpus Callosum Integrity in Alzheimer’s Disease Presenter: Ralph Kern, M.D., MHSc | 8:00 – 10:00 AM CET 🔗 Learn more about AD/PD 2025: https://adpd.kenes.com 🔗 More on Cognito Therapeutics: www.cognitotx.com #ADPD2025 #Alzheimers #Neurodegeneration #Spectris #Neuromodulation #Neurotech #FutureOfMedicine